Junjie Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Junjie Li has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
Zongshun Chen
5 shared publications- Da-Lin Lu
Department of Epidemiology, School of Medicine, Jinan University, Guangzhou, China
4 shared publications Jing Zhang
Department of Epidemiology, School of Medicine, Jinan University, Guangdong, Tianhe District, Guangdong, China
4 shared publicationsWei Chen
School of Medical and Life Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, China
4 shared publicationsXueyi Chen
4 shared publicationsJun Jiang
School of Medicine, University of Electronic Science and Technology of China, Chengdu, China; Department of Breast Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China
2 shared publications
Latest Publications
- Open Access
- 14 October 2026
- Published by Wiley in Advanced Science
- p. e78146
FAK Mediated Coordination of Extracellular Matrix Remodeling and Cellular Mechanics Impairs Nanomedicine Delivery in Solid Tumors
Tumor extracellular matrix (ECM) remodeling and cell‐intrinsic mechanical properties critically limit nanoparticle (NP) delivery, yet how these multiscale biophysical cues are coordinately regulated remains unclear. Here, we identify focal adhesion kinase (FAK/ PTK2 ) as a central mechanobiological regulator that couples ECM remodeling with cellular mechanics to control NP transport and cellular uptake. The ECM derived from patients' tumors exhibited increased stiffness and collagen density, which severely restricted NP penetration, while PTK2 emerged as a key integrin‐associated signaling hub linked to ECM organization. FAK depletion or inhibition disrupted ECM homeostasis, significantly enhanced NP penetration and cellular uptake. Mechanistically, FAK loss reduced cellular stiffness and cytoskeletal tension while increasing membrane deformability and transcriptionally reprogramming endocytic pathways, with clathrin‐mediated endocytosis as the dominant route. In vivo, FAK ablation remodeled the tumor stroma to enhance NP accumulation and penetration, and the combination of FAK inhibition with chemotherapy demonstrated potent antitumor efficacy. Together, these results establish a multiscale mechanistic paradigm in which FAK integrates ECM biophysics, cellular mechanics, and endocytic regulation to gatekeep nanomedicine delivery. Targeting FAK offers a potential strategy to enhance therapeutic penetration and efficacy in solid tumors.
- 14 October 2026
- Published by Wiley in Advanced Science
- p. e78146
Open AccessFAK Mediated Coordination of Extracellular Matrix Remodeling and Cellular Mechanics Impairs Nanomedicine Delivery in Solid Tumors
Tumor extracellular matrix (ECM) remodeling and cell‐intrinsic mechanical properties critically limit nanoparticle (NP) delivery, yet how these multiscale biophysical cues are coordinately regulated remains unclear. Here, we identify focal adhesion kinase (FAK/ PTK2 ) as a central mechanobiological regulator that couples ECM remodeling with cellular mechanics to control NP transport and cellular uptake. The ECM derived from patients' tumors exhibited increased stiffness and collagen density, which severely restricted NP penetration, while PTK2 emerged as a key integrin‐associated signaling hub linked to ECM organization. FAK depletion or inhibition disrupted ECM homeostasis, significantly enhanced NP penetration and cellular uptake. Mechanistically, FAK loss reduced cellular stiffness and cytoskeletal tension while increasing membrane deformability and transcriptionally reprogramming endocytic pathways, with clathrin‐mediated endocytosis as the dominant route. In vivo, FAK ablation remodeled the tumor stroma to enhance NP accumulation and penetration, and the combination of FAK inhibition with chemotherapy demonstrated potent antitumor efficacy. Together, these results establish a multiscale mechanistic paradigm in which FAK integrates ECM biophysics, cellular mechanics, and endocytic regulation to gatekeep nanomedicine delivery. Targeting FAK offers a potential strategy to enhance therapeutic penetration and efficacy in solid tumors.
- Open Access
- 1 October 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1915023
Efficacy and safety of neurokinin-1 receptor antagonist on cough suppression: a systematic review and meta-analysis
Introduction: The efficacy and safety of neurokinin-1 (NK-1) receptor antagonist in adults with cough remain unclear. Our objective was to systematically assess the efficacy and safety of NK-1 receptor antagonist for cough treatment using the latest available clinical evidence. Methods: A comprehensive literature retrieval was conducted across PubMed, Embase (via Ovid), the Cochrane Central Register of Controlled Trials (CENTRAL), and the ClinicalTrials.gov registry, encompassing data from database inception through 10 March 2026. This search aimed to identify randomized controlled trials (RCTs) assessing the therapeutic utility of NK-1 receptor antagonists in cough management. The abstracts and full-text articles were screened based on predefined inclusion and exclusion criteria. Meta-analysis was performed using R software (V 4.4.2). Main outcomes included the cough visual analog scale (VAS), awake objective cough frequency, urge to cough scale, 24-h cough frequency, and cough-specific patient-reported scale. Adverse events were also pooled. Results: Five RCTs comprising a total 719 participants were included, evaluating three NK-1 receptor antagonists: aprepitant, orvepitant, and serlopitant. Compared to placebo, NK-1 receptor antagonists demonstrated significant antitussive efficacy by improving cough VAS scores (mean difference [MD] = −6.90, 95 CI (−10.90, −2.90), p < 0.0001) and cough-specific patient-reported scale (standardized mean difference [SMD] = 0.50, 95 CI (0.22, 0.78), p < 0.0001). Notably, the treatment group experienced a significant reduction in the urge to cough scale (SMD: −0.31, 95% CI (−0.40, - group (RR: 1.33, 95% CI (1.15, 1.53), p < 0.0001).No significant difference was detected at the overall effect estimates of objective cough frequency. Conclusion: NK-1 receptor antagonists provide modest improvements in patient-reported subjective cough outcomes, but show no statistically significant reduction in objective cough frequency. Given the small evidence base, clinical heterogeneity among pooled conditions, and higher incidence of mild adverse events, conclusions regarding their clinical benefit must be drawn with caution. Large-scale, high-quality clinical studies are required to confirm their efficacy and safety.
- 1 October 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1915023
Open AccessEfficacy and safety of neurokinin-1 receptor antagonist on cough suppression: a systematic review and meta-analysis
Introduction: The efficacy and safety of neurokinin-1 (NK-1) receptor antagonist in adults with cough remain unclear. Our objective was to systematically assess the efficacy and safety of NK-1 receptor antagonist for cough treatment using the latest available clinical evidence. Methods: A comprehensive literature retrieval was conducted across PubMed, Embase (via Ovid), the Cochrane Central Register of Controlled Trials (CENTRAL), and the ClinicalTrials.gov registry, encompassing data from database inception through 10 March 2026. This search aimed to identify randomized controlled trials (RCTs) assessing the therapeutic utility of NK-1 receptor antagonists in cough management. The abstracts and full-text articles were screened based on predefined inclusion and exclusion criteria. Meta-analysis was performed using R software (V 4.4.2). Main outcomes included the cough visual analog scale (VAS), awake objective cough frequency, urge to cough scale, 24-h cough frequency, and cough-specific patient-reported scale. Adverse events were also pooled. Results: Five RCTs comprising a total 719 participants were included, evaluating three NK-1 receptor antagonists: aprepitant, orvepitant, and serlopitant. Compared to placebo, NK-1 receptor antagonists demonstrated significant antitussive efficacy by improving cough VAS scores (mean difference [MD] = −6.90, 95 CI (−10.90, −2.90), p < 0.0001) and cough-specific patient-reported scale (standardized mean difference [SMD] = 0.50, 95 CI (0.22, 0.78), p < 0.0001). Notably, the treatment group experienced a significant reduction in the urge to cough scale (SMD: −0.31, 95% CI (−0.40, - group (RR: 1.33, 95% CI (1.15, 1.53), p < 0.0001).No significant difference was detected at the overall effect estimates of objective cough frequency. Conclusion: NK-1 receptor antagonists provide modest improvements in patient-reported subjective cough outcomes, but show no statistically significant reduction in objective cough frequency. Given the small evidence base, clinical heterogeneity among pooled conditions, and higher incidence of mild adverse events, conclusions regarding their clinical benefit must be drawn with caution. Large-scale, high-quality clinical studies are required to confirm their efficacy and safety.
- Open Access
- 24 August 2026
- Published by Elsevier in Translational Oncology
- Vol. 72
Based on Raman spectroscopy and clinical laboratory tests: Developing a fusion model to predict neoadjuvant therapy response in breast cancer
- 24 August 2026
- Published by Elsevier in Translational Oncology
- Vol. 72
Open AccessBased on Raman spectroscopy and clinical laboratory tests: Developing a fusion model to predict neoadjuvant therapy response in breast cancer
- Open Access
- 11 November 2025
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 30 (11)
Survival outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer patients
Background: Neoadjuvant chemotherapy (NACT) has been widely used in breast cancer patients. The aim of the study was to compare survival outcomes between breast cancer patients receiving NACT, with and without complete pathologic response (pCR), and those receiving adjuvant chemotherapy (ACT). Methods: Based on the Surveillance, Epidemiology, and End Results database, we conducted a population-based cohort study including 48 350 breast cancer patients, 15 525 of whom with pCR after NACT, and 124 202 patients after ACT during the period of 2010-2021. In comparison with patients in ACT group, we assessed hazard ratios (HRs) of breast cancer-specific and overall mortality among individuals in NACT using Cox regression. Results: During the period of follow-up (median 5 years), 4800 and 8257 breast cancer–related deaths were identified among patients in NACT and ACT group, respectively. Patients in NACT group had unfavorable molecular type (human epidermal growth factor receptor 2 overexpression, triple negative), more advanced tumor features (higher grade and stage) and was more likely to undergo mastectomy and radiotherapy. Moreover, patients undergoing NACT had higher cumulative mortality rate of breast cancer (19.60% vs 10.46%), compared with those receiving ACT. After controlling for covariates, NACT patients were at increased risk of breast cancer-specific mortality (HR 1.47, 95% CI 1.41-1.53) compared with ACT patients. In contrast, NACT patients with pCR were associated with an improved breast cancer-specific survival (HR 0.59, 95% CI 0.54-0.64). The elevated risk was obviously greater among NACT patients in NACT-disfavored subgroups including lobular/mixed histology, well/moderately differentiated grade, local cancer stage, or HR+/HER2- molecular subtype (HRs 1.63-1.93). Conclusions: NACT patients have worse survival, compared with their ACT counterparts. Although patients with pCR after NACT derive significant survival benefits, NACT-disfavored subgroups may gain limited benefit from NACT, and alternative approaches should be considered.
- 11 November 2025
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 30 (11)
Open AccessSurvival outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer patients
Background: Neoadjuvant chemotherapy (NACT) has been widely used in breast cancer patients. The aim of the study was to compare survival outcomes between breast cancer patients receiving NACT, with and without complete pathologic response (pCR), and those receiving adjuvant chemotherapy (ACT). Methods: Based on the Surveillance, Epidemiology, and End Results database, we conducted a population-based cohort study including 48 350 breast cancer patients, 15 525 of whom with pCR after NACT, and 124 202 patients after ACT during the period of 2010-2021. In comparison with patients in ACT group, we assessed hazard ratios (HRs) of breast cancer-specific and overall mortality among individuals in NACT using Cox regression. Results: During the period of follow-up (median 5 years), 4800 and 8257 breast cancer–related deaths were identified among patients in NACT and ACT group, respectively. Patients in NACT group had unfavorable molecular type (human epidermal growth factor receptor 2 overexpression, triple negative), more advanced tumor features (higher grade and stage) and was more likely to undergo mastectomy and radiotherapy. Moreover, patients undergoing NACT had higher cumulative mortality rate of breast cancer (19.60% vs 10.46%), compared with those receiving ACT. After controlling for covariates, NACT patients were at increased risk of breast cancer-specific mortality (HR 1.47, 95% CI 1.41-1.53) compared with ACT patients. In contrast, NACT patients with pCR were associated with an improved breast cancer-specific survival (HR 0.59, 95% CI 0.54-0.64). The elevated risk was obviously greater among NACT patients in NACT-disfavored subgroups including lobular/mixed histology, well/moderately differentiated grade, local cancer stage, or HR+/HER2- molecular subtype (HRs 1.63-1.93). Conclusions: NACT patients have worse survival, compared with their ACT counterparts. Although patients with pCR after NACT derive significant survival benefits, NACT-disfavored subgroups may gain limited benefit from NACT, and alternative approaches should be considered.
- 1 April 2025
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 32 (6) , 4055-4056
ASO Author Reflections: Serum Enzymes as Predictive Biomarkers for Pathologic Complete Response in HER2-Positive Breast Cancer
- 1 April 2025
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 32 (6) , 4055-4056
ASO Author Reflections: Serum Enzymes as Predictive Biomarkers for Pathologic Complete Response in HER2-Positive Breast Cancer
- 24 March 2025
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 32 (6) , 4061-4062
ASO Visual Abstract: Serum Enzymes and Pathologic Complete Response to the Addition of Targeted Therapy in Neoadjuvant Chemotherapy for HER2-Positive Breast Cancer Patients
- 24 March 2025
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 32 (6) , 4061-4062
ASO Visual Abstract: Serum Enzymes and Pathologic Complete Response to the Addition of Targeted Therapy in Neoadjuvant Chemotherapy for HER2-Positive Breast Cancer Patients
- 11 March 2025
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 32 (6) , 4008-4016
Serum Enzymes and Pathologic Complete Response to the Addition of Targeted Therapy in Neoadjuvant Chemotherapy for HER2-Positive Breast Cancer Patients
This study investigated the association between circulating alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatine kinase (CK), lactate
- 11 March 2025
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 32 (6) , 4008-4016
Serum Enzymes and Pathologic Complete Response to the Addition of Targeted Therapy in Neoadjuvant Chemotherapy for HER2-Positive Breast Cancer Patients
This study investigated the association between circulating alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatine kinase (CK), lactate
- Open Access
- 14 September 2024
- Published by Elsevier in Materials Today Bio
- Vol. 28, 101245
Aligned fibrous scaffolds promote directional migration of breast cancer cells via caveolin-1/YAP-mediated mechanosensing
- 14 September 2024
- Published by Elsevier in Materials Today Bio
- Vol. 28, 101245
Open AccessAligned fibrous scaffolds promote directional migration of breast cancer cells via caveolin-1/YAP-mediated mechanosensing
- Open Access
- 9 May 2024
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 22 (1) , 1-13
Association between pathologic complete response and biochemical indicators after neoadjuvant therapy for HER2-positive breast cancer
Purpose: This study investigated the changes in the fasting blood glucose (FBG), fasting triglyceride (FTG), and fasting total cholesterol (FTC) levels during neoadjuvant therapy (NAT) for human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) and the association with pathologic complete response (pCR). Methods: Relevant data from Sichuan Cancer Hospital from June 2019 to June 2022 were collected and analyzed, and FBG, FTG, and FTC were divided into baseline, change, and process groups, which were grouped to analyze the changes after receiving NAT and the association with pCR. Results: In the estrogen receptor (ER)-negative subgroup, patients with low levels of FTG in the process group were more likely to achieve pCR compared to high levels, and in the progesterone receptor (PR)-negative subgroup, patients with lower FTG compared to higher FTG after receiving NAT was more likely to achieve pCR. Conclusions: Patients with HER2-positive BC undergoing NAT develop varying degrees of abnormalities (elevated or decreased) in FBG, FTG, and FTC; moreover, the status of FTG levels during NAT may predict pCR in ER-negative or PR-negative HER2-positive BC.Early monitoring and timely intervention for FTG abnormalities may enable this subset of patients to increase the likelihood of obtaining a pCR along with management of abnormal markers.
- 9 May 2024
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 22 (1) , 1-13
Open AccessAssociation between pathologic complete response and biochemical indicators after neoadjuvant therapy for HER2-positive breast cancer
Purpose: This study investigated the changes in the fasting blood glucose (FBG), fasting triglyceride (FTG), and fasting total cholesterol (FTC) levels during neoadjuvant therapy (NAT) for human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) and the association with pathologic complete response (pCR). Methods: Relevant data from Sichuan Cancer Hospital from June 2019 to June 2022 were collected and analyzed, and FBG, FTG, and FTC were divided into baseline, change, and process groups, which were grouped to analyze the changes after receiving NAT and the association with pCR. Results: In the estrogen receptor (ER)-negative subgroup, patients with low levels of FTG in the process group were more likely to achieve pCR compared to high levels, and in the progesterone receptor (PR)-negative subgroup, patients with lower FTG compared to higher FTG after receiving NAT was more likely to achieve pCR. Conclusions: Patients with HER2-positive BC undergoing NAT develop varying degrees of abnormalities (elevated or decreased) in FBG, FTG, and FTC; moreover, the status of FTG levels during NAT may predict pCR in ER-negative or PR-negative HER2-positive BC.Early monitoring and timely intervention for FTG abnormalities may enable this subset of patients to increase the likelihood of obtaining a pCR along with management of abnormal markers.
- 16 February 2024
- Published by Elsevier in Clinical Breast Cancer
- Vol. 24 (4) , 376-383
A Molecular Typing Method for Invasive Breast Cancer by Serum Raman Spectroscopy
- 16 February 2024
- Published by Elsevier in Clinical Breast Cancer
- Vol. 24 (4) , 376-383
A Molecular Typing Method for Invasive Breast Cancer by Serum Raman Spectroscopy